SEARCH

SEARCH BY CITATION

References

  • 1
    Truelove SC, Jewell DP. Intensive intravenous regimen for severe attacks of ulcerative colitis. Lancet. 1974; 1: 10671070.
  • 2
    Hyde GM, Jewell DP. The management of severe ulcerative colitis. Aliment Pharmacol Ther. 1997; 11: 419424.
  • 3
    Lichtiger S, Present DH, Kornbluth A, et al. Cyclosporin in severe ulcerative colitis refractory to steroid therapy. N Engl J Med. 1994; 330: 18411845.
  • 4
    Carbonnel F, Boruchowicz A, Duclos B, et al. Intravenous cyclosporine in attacks of ulcerative colitis: short term and long term responses. Dig Dis Sci. 1996; 41: 24712476.
  • 5
    Stack WA, Long RG, Hawkey CJ. Short- and long-term outcome of patients treated with cyclosporin for severe acute ulcerative colitis. Aliment Pharmacol Ther. 1998; 12: 973978.
  • 6
    Van Gossum A, Schmit A, Adler M, et al. Short- and long-term efficacy of cyclosporin administration in patients with acute severe ulcerative colitis. Belgian IBD Group. Acta Gastroenterol Belg. 1997; 60: 197200.
  • 7
    Cohen RD, Stein R, Hanauer SB. Intravenous cyclosporine in ulcerative colitis: a five-year experience. Am J Gastroenterol. 1999; 94: 15871592.
    Direct Link:
  • 8
    Hyde GM, Thillainayagam AV, Jewell DP. Intravenous cyclosporin as rescue therapy in severe ulcerative colitis. Eur J Gastroenterol Hepatol. 1998; 10: 411415.
  • 9
    Van Assche G, D'Haens G, Noman M, et al. Randomized double-blind comparison of 4 mg/kg versus 2 mg/kg intravenous cyclosporin in severe ulcerative colitis. Gastroenterology. 2003; 125: 10251031.
  • 10
    Friman S, Bäckman L. A new microemulsion formulation of cyclosporin. Clin Phamacokinet. 1996; 30: 181193.
  • 11
    Latteri M, Angeloni G, Gentiloni Silveri N, et al. Pharmacokinetics of cyclosporin microemulsion in patients with inflammatory bowel disease. Clin Pharmacokinet. 2001; 40: 473483.
  • 12
    Actis GC, Aimo G, Priolo G, et al. Efficacy and efficiency of oral microemulsion cyclosporin versus intravenous and soft gelatin capsule cyclosporin in the treatment of severe steroid-refractory ulcerative colitis: an open-label retrospective trial. Inflamm Bowel Dis. 1998; 4: 276279.
  • 13
    Navazo L, Salata H, Morales S, et al. Oral microemulsion cyclosporin in the treatment of steroid-refractory attacks of ulcerative and indeterminate colitis. Scand J Gastroenterol. 2001; 36: 610614.
  • 14
    Actis GC, Lagget M, Rizzetto M, et al. Long-term efficacy of oral microemulsion cyclosporin for refractory ulcerative colitis. Minerva Med. 2004; 95: 6570.
  • 15
    Campbell S, Travis S, Jewell D. Cyclosporin use in acute ulcerative colitis: a long-term experience. Eur J Gastroenterol Hepatol. 2005; 17: 7984.
  • 16
    DeGroen PC, Aksamit AJ, Rakela J, et al. Central nervous system toxicity after liver transplantation: the role of cyclosporine and cholesterol. N Engl J Med. 1987; 317: 861866.
  • 17
    Hamlin PJ, Shah MN, Scott N, et al. Systemic cytomegalovirus infection complicating ulcerative colitis: a case report and review of the literature. Postgrad Med J. 2004; 80: 233235.
  • 18
    Arnon TI, Achdout H, Levi O, et al. Inhibition of the NKp30 activating receptor by pp65 of human cytomegalovirus. Nat Immunol. 2005; 6: 515523.
  • 19
    Grant D, Kneteman N, Tchervenkov J, et al. Peak cyclosporine levels (Cmax) correlate with freedom from liver graft rejection: results of a prospective, randomized comparison of Neoral and Sandimmune for liver transplantation (NOF-8). Transplantation. 1999; 67: 11331137.
  • 20
    Levy G, Burra P, Cavallari A, et al. Improved clinical outcomes for liver transplant recipients using cyclosporine monitoring based on 2-hr post-dose levels (C2). Transplantation. 2002; 73: 953959.
  • 21
    Probert CSJ, Hearing SD, Schreiber S, et al. Infliximab in moderately severe glucocorticoid resistant ulcerative colitis: a randomised controlled trial. Gut. 2003; 52: 9981002.
  • 22
    Jarnerot G, Hertervig E, Friis-Liby IL, et al. Infliximab as rescue therapy in severe to moderately severe ulcerative colitis: a randomised placebo controlled study. Gastroenterology. 2005; 128: 18051811.
  • 23
    Rutgeerts P, Sandborn WJ, Feagan BG, et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2005; 353: 24622476.
  • 24
    Stein CM, Murray JJ, Wood AJ. Inhibition of stimulated interleukin-2 production in whole blood: a practical measure of cyclosporine effect. Clin Chem. 1999; 45: 14771484.
  • 25
    Giese T, Zeier M, Schemmer P, et al. Monitoring of NFAT-regulated gene expression in the peripheral blood of allograft recipients: a novel perspective toward individually optimized drug doses of cyclosporine A. Transplantation. 2004; 77: 339344.
  • 26
    Moskovitz DN, Van Assche G, Maenhout B, et al. Colectomy rates after cyclosporine induced remission: 7 years experience in ulcerative colitis. Gastroenterology. 2005; 128: A583.